Arresten, a Collagen-Derived Angiogenesis Inhibitor, Suppresses Invasion of Squamous Cell Carcinoma

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Aikio, Mari ^a   Alahuhta, Ilkka ^a   Nurmenniemi, Sini ^a   Suojanen, Juho ^b   Palovuori, Riitta ^a   Teppo, Susanna ^a   Sorsa, Timo ^b   López Otín, Carlos ^c   Pihlajaniemi, Taina ^a   Salo, Tuula ^a,d   Heljasvaara, Ritva ^a   Nyberg, Pia ^a,d  

^a UNIVERSITY OF OULU   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^d OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; COLLAGEN TYPE 4; METICRANE; UVOMORULIN; VERY LATE ACTIVATION ANTIGEN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASEMENT MEMBRANE; BIOLOGICAL ACTIVITY; CANCER INVASION; CARCINOGENESIS; CELL CONTACT; CELL DEATH; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SPREADING; CELL STRUCTURE; CELL TYPE; EXTRACELLULAR MATRIX; HYPOXIA; IMPEDANCE; MONOLAYER CULTURE; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SQUAMOUS CELL CARCINOMA;

EID: 84870807284     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051044     Document Type: Article

References (57)

1. Nyberg P, Xie L, Kalluri R, (2005) Endogenous inhibitors of angiogenesis. Cancer Res 65: 3967-3979.
2. Nyberg P, Salo T, Kalluri R, (2008) Tumor microenvironment and angiogenesis. Front Biosci 13: 6537-6553.
3. Colorado PC, Torre A, Kamphaus G, Maeshima Y, Hopfer H, et al. (2000) Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res 60: 2520-2526.
4. Kamphaus GD, Colorado PC, Panka DJ, Hopfer H, Ramchandran R, et al. (2000) Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 275(2): 1209-1215.
5. Pasco S, Ramont L, Venteo L, Pluot M, Maquart FX, et al. (2004) In vivo overexpression of tumstatin domains by tumor cells inhibits their invasive properties in a mouse melanoma model. Exp Cell Res 301(2): 251-265.
6. Maeshima Y, Colorado PC, Torre A, Holthaus KA, Grunkemeyer JA, et al. (2000) Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 275(28): 21340-21348.
7. Mundel TM, Yliniemi AM, Maeshima Y, Sugimoto H, Kieran M, et al. (2008) Type IV collagen alpha6 chain-derived noncollagenous domain 1 (alpha6(IV)NC1) inhibits angiogenesis and tumor growth. Int J Cancer 122(8): 1738-1744.
8. Petitclerc E, Boutaud A, Prestayko A, Xu J, Sado Y, et al. (2000) New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem 275(11): 8051-8061.
9. Pasco S, Monboisse JC, Kieffer N, (2000) The alpha 3(IV)185-206 peptide from noncollagenous domain 1 of type IV collagen interacts with a novel binding site on the beta 3 subunit of integrin alpha Vbeta 3 and stimulates focal adhesion kinase and phosphatidylinositol 3-kinase phosphorylation J Biol Chem. 275(42): 32999-33007.
10. Maeshima Y, Yerramalla UL, Dhanabal M, Holthaus KA, Barbashov S, et al. (2001) Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis J Biol Chem. 276(34): 31959-31968.
11. Magnon C, Galaup A, Mullan B, Rouffiac V, Bouquet C, et al. (2005) Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with alphavbeta3 and alphavbeta5 integrins. Cancer Res 65(10): 4353-4361.
12. Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, et al. (2003) Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 3(6): 589-601.
13. Pedchenko V, Zent R, Hudson BG, (2004) Alpha(v)beta3 and alpha(v)beta5 integrins bind both the proximal RGD site and non-RGD motifs within noncollagenous (NC1) domain of the alpha3 chain of type IV collagen: implication for the mechanism of endothelia cell adhesion. J Biol Chem 279(4): 2772-2780.
14. Rehn M, Veikkola T, Kukk-Valdre E, Nakamura H, Ilmonen M, et al. (2001) Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A 98: 1024-1029.
15. Brassart-Pasco S, Sénéchal K, Thevenard J, Ramont L, Devy J, et al. (2012) Tetrastatin, the NC1 domain of the α4(IV) collagen chain: a novel potent anti-tumor matrikine. PLoS One 7(4): e29587.
16. Sudhakar A, Nyberg P, Keshamouni VG, Mannam AP, Li J, et al. (2005) Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin. J Clin Invest 115: 2801-2810.
17. Boosani CS, Sudhakar A, (2006) Cloning, purification, and characterization of a non-collagenous anti-angiogenic protein domain from human alpha1 type IV collagen expressed in Sf9 cells. Protein Expr Purif 49: 211-218.
18. Nyberg P, Xie L, Sugimoto H, Colorado P, Sund M, et al. (2008) Characterization of the anti-angiogenic properties of arresten, an alpha1beta1 integrin-dependent collagen-derived tumor suppressor. Exp Cell Res 314: 3292-3305.
19. Boosani CS, Nalabothula N, Munugalavadla V, Cosgrove D, Keshamoun VG, et al. (2009) FAK and p38-MAP kinase-dependent activation of apoptosis and caspase-3 in retinal endothelial cells by alpha1(IV)NC1. Invest Ophthalmol Vis Sci 50: 4567-4575.
20. Assadian S, El-Assaad W, Wang XQ, Gannon PO, Barrès V, et al. (2012) p53 inhibits angiogenesis by inducing the production of Arresten. Cancer Res 72: 1270-1279.
21. Tse JC, Kalluri R, (2007) Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem 101: 816-829.
22. Kalluri R, Weinberg RA, (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119(6): 1420-1428.
23. Thiery JP, Acloque H, Huang RY, Nieto MA, (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5): 871-890.
24. Talbot LJ, Bhattacharya SD, Kuo PC, (2012) Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies. Int J Biochem Mol Biol 3(2): 117-136.
25. Cox TR, Erler JT, (2011) Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis Model Mech 4: 165-178.
26. Bissell MJ, Radisky D, (2001) Putting tumours in context. Nat Rev Cancer 1: 46-54.
27. Shintani Y, Maeda M, Chaika N, Johnson KR, Wheelock MJ, (2007) Collagen I promotes epithelial-to-mesenchymal transition in lung cancer cells via transforming growth factor-beta signaling. Am J Respir Cell Mol Biol 38: 95-104.
28. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, et al. (2009) Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139(5): 891-906.
29. Medici D, Nawshad A, (2010) Type I collagen promotes epithelial-mesenchymal transition through ILK-dependent activation of NF-kappaB and LEF-1. Matrix Biol 29(3): 161-165.
30. Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, et al. (2009) Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15(1): 35-44.
31. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, et al. (2007) Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 213(2): 374-383.
32. Giehl K, Menke A, (2008) Microenvironmental regulation of E-cadherin-mediated adherens junctions. Front Biosci 13: 3975-3985.
33. Guo W, Giancotti FG, (2004) Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5: 816-826.
34. Khoshnoodi J, Pedchenko V, Hudson BG, (2008) Mammalian collagen IV. Microsc Res Tech. 71(5): 357-70.
35. Giaever I, Keese CR, (1984) Monitoring fibroblast behavior in tissue culture with an applied electric field. Proc Natl Acad Sci U S A 81: 3761-3764.
36. Giaever I, Keese CR, (1991) Micromotion of mammalian cells measured electrically. Proc Natl Acad Sci USA 88: 7896-7900.
37. Lo CM, Keese CR, Giaever I, (1995) Impedance analysis of MDCK cells measured by electric cell-substrate impedance sensing. Biophys J 69: 2800-2807.
38. Avizienyte E, Wyke AW, Jones RJ, McLean GW, Westhoff MA, et al. (2002) Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling. Nat Cell Biol 4: 632-638.
39. Zhang W, Alt-Holland A, Margulis A, Shamis Y, Fusenig NE, et al. (2006) E-cadherin loss promotes the initiation of squamous cell carcinoma invasion through modulation of integrin-mediated adhesion. J Cell Sci 119: 283-291.
40. Wells A, Chao YL, Grahovac J, Wu Q, Lauffenburger DA, (2011) Epithelial and mesenchymal phenotypic switching modulate cell motility in metastasis. Front Biosci 16: 815-837.
41. Canel M, Serrels A, Miller D, Timpson P, Serrels B, et al. (2010) Quantitative in vivo imaging of the effects of inhibiting integrin signaling via Src and FAK on cancer cell movement: effects on E-cadherin dynamics. Cancer Res 70: 9413-9422.
42. Schuh JC, (2004) Trials, tribulations, and trends in tumor modeling in mice. Toxicol Pathol 32Suppl 1: 53-66.
43. Berx G, Raspe E, Christofori G, Thiery JP, Sleeman JP, (2007) Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clin Exp Metastasis 24: 587-597.
44. Sudhakar A, Sugimoto H, Changqing Y, Lively J, Zeisberg M, et al. (2003) Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci USA 100: 4766-4771.
45. Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, et al. (1997) Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 137: 231-245.
46. Wang XQ, Lindberg FP, Frazier WA, (1999) Integrin-associated protein stimulates alpha2beta1-dependent chemotaxis via Gi-mediated inhibition of adenylate cyclase and extracellular-regulated kinases. J Cell Biol 147: 389-400.
47. Wu Y, Chen L, Zheng PS, Yang BB, (2002) beta 1-Integrin-mediated glioma cell adhesion and free radical-induced apoptosis are regulated by binding to a C-terminal domain of PG-M/versican. J Biol Chem 277: 12294-12301.
48. Gao D, Joshi N, Choi H, Ryu S, Hahn M, et al. (2012) Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res 72: 1384-1394.
49. Koenig A, Mueller C, Hasel C, Adler G, Menke A, (2006) Collagen type I induces disruption of E-cadherin mediated cell-cell contacts and promotes proliferation of pancreatic carcinoma cells. Cancer Res 66: 4662-4671.
50. Zeisberg M, Bonner G, Maeshima Y, Colorado P, Müller GA, et al. (2001) Renal fibrosis: collagen composition and assembly regulates epithelial-mesenchymal transdifferentiation. Am J Pathol 159: 1313-1321.
51. Calabrese EJ, (2005) Cancer biology and hormesis: human tumor cell lines commonly display hormetic (biphasic) dose responses.Crit Rev Toxicol. 35(6): 463-582.
52. Celik I, Surucu O, Dietz C, Heymach JV, Force J, et al. (2005) Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res 65: 11044-11050.
53. Ramazani M, Lundin C, Sund M, (2011) Increased circulating levels of basement-membrane components in patients with abdominal aortic aneurysms-a pilot study. Eur J Vasc Endovasc Surg 42(4): 484-7.
54. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, et al. (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438(7069): 820-827.
55. Kylmäniemi M, Oikarinen A, Oikarinen K, Salo T, (1996) Effects of dexamethasone and cell proliferation on the expression of matrix metalloproteinases in human mucosal normal and malignant cells. J Dent Res 75: 919-926.
56. Nurmenniemi S, Sinikumpu T, Alahuhta I, Salo S, Sutinen M, et al. (2009) A novel organotypic model mimics the tumor microenvironment. Am J Pathol 175: 1281-1291.
57. Brideau G, Mäkinen MJ, Elamaa H, Tu H, Nilsson G, et al. (2007) Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res 67: 11528-11535.